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ABSTRACT
Background: This study tested the hypothesis that contemporary menopausal hormonal therapy
(MHT) increases the risk of biliary tract cancer. The risk of cancer of the biliary tract (gallbladder and
extra-hepatic bile ducts) may be increased following estrogen exposure.
Material and methods: This was a nationwide population-based matched cohort study in Sweden.
Data from the Swedish Prescribed Drug Register identified all women exposed to systemic MHT in
2005–2012. Group-level matching (1:3 ratio) was used to select women unexposed to MHT from the
same study base, matched for history of delivery, thrombotic events, hysterectomy, age, smoking- and
alcohol related diseases, obesity, and diabetes. Conditional logistic regression was used to calculate
odds ratios (OR) and 95% confidence intervals (CI).
Results: Comparing 290,186 women exposed to MHT with 870,165 unexposed, MHT did not increase
the OR of biliary tract cancer. The OR of gallbladder cancer was rather decreased in MHT users (OR
0.58, 95% CI 0.43–0.79), but this association became attenuated and statistically non-significant after
adjusting for gallstone disease (OR 0.84, 95% CI 0.60–1.15). The OR of extra-hepatic bile duct cancers
was 0.83 (95% CI 0.61–1.15). There were no clear differences when the analyses were stratified for
estrogen or estrogen/progestogen combinations. MHT increased the risk of gallstone disease (OR 6.95,
95% CI 6.64–7.28).
Conclusions: Contemporary MHT does not seem to increase the risk of biliary tract cancer. The
decreased risk of gallbladder cancer may be explained by the increased use of surgery for symptom-
atic gallstones in MHT users.
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Introduction
Biliary tract cancers comprising cancers of the gallbladder
and the extra-hepatic bile ducts, including the ampulla, are
highly lethal [1]. Gallbladder cancer and cancers of the extra-
hepatic bile ducts share many epidemiological characteristics
and risk factors such as primary sclerosing cholangitis, obes-
ity and diabetes. There are, however, some important differ-
ences [1]. Most notably, gallbladder cancer occurs more
frequently in women, whereas extra-hepatic tumors are more
evenly distributed between the sexes [2]. The reason for the
sex difference in gallbladder cancer is not entirely under-
stood, although the association with gallstone disease is a
potential explanation [3]. Gallstone disease is more common
in women and is associated with estrogen exposure [4].
Thus, gallstone disease seems to be related to both estrogen
exposure and BTC. Furthermore, some studies investigating a
potential hormonal hypothesis, have suggested an increased
risk of gallbladder cancer with increasing parity and other
reproductive factors, both used as proxies for endogenous
hormone exposure [5–7]. However, the risk of BTC following
exogenous estrogen exposure has rarely been studied.
Menopausal hormone therapy (MHT) is indicated to alleviate
vaso-motor symptoms, osteoporosis, and vaginal atrophy in
menopausal women [8,9]. An increased risk of breast and
endometrial cancer following MHT has been reported
[8,10,11]. Additionally, some studies have indicated
decreased risks of some gastro-intestinal cancers following
MHT exposure, particularly adenocarcinoma of the esopha-
gus, stomach, and colon [11,12]. The evidence of an associ-
ation between MHT and BTC is inconsistent. Some studies
have reported an increased risk of BTC in MHT exposed
women, whereas other studies have shown opposing results
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[13–15]. Previous studies have been small (i.e., fewer than 30
women with cancer) and have seldom been population-
based, introducing a risk of chance errors and selection bias,
respectively. Furthermore, some previous studies have not
distinguished gallbladder cancer from other types of biliary
tract cancer or even liver cancers, making results difficult to
interpret [13].
Estrogen and progesterone receptors are expressed in
both normal and dysplastic biliary tract tissue and in vitro
studies have shown that estrogen exposure increases cancer
growth, whereas estrogen receptor antagonists can inhibit
cancer growth in biliary tract cancer cell lines [16–18]. Thus,
there is biological support for the hypothesis that female sex
hormone exposure increases the risk of BTC.
This study was prompted by the unclear associations
between sex hormone exposure and BTC risk. A population-
based cohort study was undertaken to test whether the risk
of BTC is increased in contemporary MHT users compared
with non-users in Sweden.
Material and methods
Study design
This was a nationwide Swedish population-based, matched
cohort study investigating the relative risk of BTC following
contemporary MHT, described in more detail elsewhere
[19–22]. Swedish women aged 40 years or older who
exposed to MHT between 1 July 2005 and 31 December
2012 were considered ever-users. Study subjects were identi-
fied through the Swedish Prescribed Drug Register.
Unexposed control subjects were matched women without
MHT drug prescriptions from the same source population
and during the same time period as those exposed. Newly
diagnosed BTC was assessed by linkage to the Swedish
Cancer Register. Women with a history of cancer prior to the
start of the study were excluded. To assess a potential medi-
ating effect of gallstones, this study also investigated the
association between MHT and gallstone disease. This was
performed using gallstone disease as the outcome in a sep-
arate analysis, and also as a covariate in the analyses of BTC.
All potential confounders were assessed by record linkage.
The Regional Ethics Review Board in Stockholm, Sweden,
approved the study.
Data sources and data collection
The Swedish Prescribed Drug Register was established in July
2005. The register includes all prescribed and dispensed
drugs in Sweden [23]. The register is maintained by the
National Board of Health and Welfare and data are trans-
ferred from pharmacies on a monthly basis. The register cov-
ers the whole of Sweden and is 99.7% complete [23].
Exposure data, including Anatomical Therapeutic Chemical
(ATC) codes, dates of drug dispensation, and mode of admin-
istration were collected from this register.
The Swedish Cancer Register, established in 1958, includes
information on newly diagnosed cancers in Sweden and is of
excellent overall quality, but may be less complete concern-
ing BTC specifically [24,25]. Data on cancer diagnosis, ana-
tomical location and histological subtype were extracted
from this register.
The Swedish Causes of Death Register was used to establish
date of death used for censoring. The register was started in
1961 and is of high overall quality, with 100% completeness
in recording of deaths in Sweden [26].
The Swedish Patient Register was established in 1964 and
contains information on diagnoses and surgical procedures.
The register is 100% complete from 1987 onwards and is of
high overall accuracy for diagnoses and surgical procedures
[27,28]. The register was used to collect information on past or
current medical conditions, patient data, presence of gallstone
disease, previous hysterectomy (surgical removal of the uterus),
and cholecystectomy (surgical gallbladder removal).
The personal identity number, assigned to all Swedish res-
idents, was used for accurate data collection of all individuals
from the registers [29].
Matching procedure
Group-level matching (1:3 ratio) was used to select a cohort of
unexposed women from the same study base, exactly matched
for history of delivery (yes or no), thrombotic events (yes or
no), and hysterectomy (yes or no). This procedure created
eight strata in which exact matching was performed for each
variable. Furthermore, unexposed subjects within each stratum
were matched for age (year of birth), diabetes (yes or no),
obesity (yes or no), smoking-related disease (yes or no), and
alcohol-related disease (yes or no) using the nearest neighbor
strategy [30]. Status of the matching variables was based on
data retrieved from the Patient Register.
Follow-up
The cohort was followed up until BTC diagnosis, death, or
end of study period, whichever occurred first. Additionally,
cohort members diagnosed with cancers other than BTC
were censored at the date of cancer diagnosis. For the gall-
bladder cancer analysis, women with a history of cholecyst-
ectomy prior to MHT exposure were excluded from the
analyses because these individuals were not at risk of devel-
oping gallbladder cancer.
Exposure
Women of at least 40 years of age, receiving one or more
prescriptions of systemic MHT drugs during the study
period were considered exposed. MHT drugs were defined
by the ATC codes: ‘G03C’ (estrogens), ‘G03D’ (progestins),
and ‘G03F’ (estrogens and progestins in combination). Only
oral and transdermal drugs were considered since these
represent systemic treatment. Users of progestins only were
excluded, because of the estrogen-based hypothesis of this
study. MHT is not available as over-the-counter drugs
in Sweden.
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Outcome
The primary outcome was BTC diagnosis identified in the
Swedish Cancer Register. The ICD-10 codes C23.9 and C24
were used to identify gallbladder cancer and cancer of the
extra-hepatic bile ducts, respectively. Because of the similar-
ities in etiology, ampullary cancers, and cancers of the extra-
hepatic bile ducts were grouped into one category; extra-
hepatic bile duct cancers. Gallbladder cancer and extra-hep-
atic bile duct cancers were analyzed separately. Furthermore,
only adenocarcinomas were included to avoid potential bias
by tumor biology differences. Gallstone disease was a sec-
ondary outcome and the association with MHT was eval-
uated in separate analyses.
Statistical analyses
The risk of BTC comparing women exposed to MHT with
those unexposed to MHT was assessed using multivariable
conditional logistic regression adjusted for all eight matching
variables and osteoporosis providing odds ratios (OR) with
95% confidence intervals (CI) since the group-matching pro-
cedure neutralized the effect of follow-up time, and no sub-
stitute date was assigned for the never-users to assess the
duration of follow-up [22]. MHT exposure was categorized as
a binary variable (ever or never) and the analyses were strati-
fied according to the type of MHT regimen, either estrogen
only or estrogen and progestogen combinations. As well as
the matching procedure described above, we also adjusted
for all matching variables in a multivariable model using the
same categories as presented above. Additionally, osteopor-
osis was added as a potential confounder to further limit the
effect of confounding by indication.
For gallbladder cancer, additional analyses were per-
formed to evaluate a potentially mediating role of gallstone
disease. First, we excluded subjects with gallstone disease
diagnosed prior to the start of the study to evaluate any
influence of gallstone disease on the association between
MHT and gallbladder cancer risk. Second, a model in which
gallstone disease was the primary outcome was fitted to
evaluate the risk of gallstone associated with MHT in subjects
without any recorded gallstone disease or cholecystectomy
prior to the start of the study.
All calculations were performed using the statistical soft-
ware STATA, version 13.1 (StataCorp. 2013, StataCorp LP,
College Station, TX).
Results
Study participants
The study included 1,160,351 women. Of these, 290,186 were
exposed to MHT and 870,165 were unexposed.
Characteristics of the study participants are presented in
Table 1. The mean follow-up time among MHT users was 5.6
years and the median MHT exposure time was 4.9 years. The
median age at inclusion was 57 years. The ratio of estrogen-
only containing regimens versus combination regimens was
close to 1.
Menopausal hormone therapy and risk of
gallbladder cancer
In total, 51 and 168 cases of gallbladder cancer were identi-
fied in the MHT exposed group and the unexposed group,
respectively. The OR of gallbladder cancer was not increased,
but rather decreased, when comparing exposed with unex-
posed women (adjusted OR 0.58, 95% CI 0.43–0.79) (Table 2).
The ORs for regimens containing only estrogen and combin-
ation regimens were 0.66 (95% 0.46–0.94) and 0.47 (95% CI
0.28–0.78), respectively. After excluding those with a history
of gallstones, the decrease became statistical insignificant
(adjusted OR 0.84, 95% CI 0.60–1.15); yet the protective
effect was more pronounced among those with a history of
gallstones (adjusted OR 0.13, 95% CI 0.05–0.36) (Table 2).
Menopausal hormone therapy and risk of extra-hepatic
bile duct cancer
In total, 48 cancers were identified in MHT exposed women
and 174 cancers were identified in unexposed women. MHT
exposure did not increase the risk of extra-hepatic bile duct
cancer (OR 0.83, 95% 0.61–1.15). Stratification for MHT regi-
men showed no statistically significant associations with
extra-hepatic bile duct cancers (Table 2).
Table 1. Characteristics of exposed and matched unexposed cohort members.
Variable Exposed subjects Unexposed subjects in the matched cohort
Total (%) 290,186 (100) 870,165 (100)
Matching and/or confounding variables (%)
Delivery 117,861 (40.6) 353,282 (40.6)
Thrombotic events 40,316 (13.9) 120,931 (13.9)
Hysterectomy 51,811 (17.9) 155,138 (17.8)
Diabetes 15,936 (5.5) 48,422 (5.6)
Obesity 5,146 (1.8) 15,526 (1.8)
Smoking 13,601 (4.7) 40,994 (4.7)
Alcohol 7,293 (2.5) 21,455 (2.5)
Osteoporosis 8,256 (2.9) 22,764 (2.6)
Cholecystectomy 25,553 (8.6) 49,818 (5.7)
Gallstone disease 29,102 (10.0) 79,933 (9.2)
MHT subtypes (%)
Estrogen only 135,988 (46.9) N/a
Esotrogen/progestin combination 154,198 (53.1) N/a
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Menopausal hormone therapy and risk of
gallstone disease
MHT increased the risk of diagnosed gallstone disease in
subjects with no prior history of gallstones (OR 6.95, 95% CI
6.64–7.28) and the increase remained across MHT regimens
(Table 2).
Discussion
This study found no support for the hypothesis that contem-
porary MHT increases the risk of biliary tract cancer. A strong
association between MHT exposure and gallstone disease
was confirmed.
The strengths of the study are the population-based
design and large sample size which minimize selection bias
and random error, respectively. This study is, to our know-
ledge, the largest to address the association between MHT
and biliary tract cancer, which made it possible to separately
analyze gallbladder cancer and extra-hepatic bile duct can-
cer. Furthermore, the adjustment for several factors associ-
ated with the initiation of MHT and complete follow-up
counteract bias from confounding, misclassification, and
selection. All data on cancer outcome, confounding factors,
and exposure data were recorded independently which
counteract information bias. As in propensity-score matching,
the group-level matching enabled us to create two groups
with a similar probability of receiving MHT, therefore, limiting
the risk of selection bias and confounding. This matched
cohort design also allowed for both groups, MHT-users and
non-users, to be balanced on several known and unknown
confounders. Adding the matching variables to the statistical
models did not change the results, showing that the match-
ing was successful. This procedure also circumvents the
problem with exposure time for never-users (who do not
have a start date of exposure). A limitation is the relatively
short follow-up time after MHT. It is likely that the effect of
MHT on biliary tract cancer carcinogenesis is in some manner
time dependent. So, it is conceivable that the follow-up time
in the present study was too short for MHT to have exerted
a significant role in biliary tract cancer development. In an
effort to evaluate duration of MHT, the exposure variable
was re-categorized into three categories. However, since
there was no information of MHT use prior to the start of
the study, these analyses were restricted to 2006 and
onwards, reducing the cohort size rather drastically, making
the precision limited. Although the information in the
Swedish Cancer Register is of high overall quality, a previous
study from our group raised concerns about the complete-
ness of the Swedish Cancer Register regarding BTC specific-
ally [24]. However, there is no reason to believe that under-
reporting of BTC was associated with MHT and any con-
founding due to under-reporting should be non-differential.
No detailed information about reproductive factors was avail-
able in this study. However, it is unlikely that MHT is
dependent on reproductive factors such as parity or age at
the birth of the first child. Furthermore, the statistical analy-
ses were adjusted for known potential confounding factors
such as diabetes and obesity, yet information on body mass
index was unavailable. Obesity is a risk factor for gallbladder
cancer, and weight may be associated with the age of onset
and severity of menopausal symptoms [31] and consequently
MHT use, so there may be residual confounding by body
weight. Residual confounding by other known or unknown
factors cannot be completely excluded, but this error should
be limited by the group-level matching on several variables,
a design that mimics a randomized trial. Concerning obesity
specifically, if exposed women would be more likely to
receive MHT, a possible effect of confounding on the results
cannot be ruled out. There have been some reports indicat-
ing that MHT users are lighter than non-users, thus residual
confounding could in part explain the decreased point esti-
mates in this study.
The previous literature addressing the risk of BTC follow-
ing MHT exposure is scarce. Some previous studies, where
no distinction of different tumor locations within the biliary
tract was made, have shown conflicting results. One fairly
large study (75 cases of BTC) showed no effect of MHT on
overall BTC risk [7]. A small study (13 cases of BTC or liver
cancer) reported a decreased risk of BTC, but it was not pos-
sible to discriminate BTC from liver cancers, making the
results difficult to interpret [13]. Furthermore, in previous
studies where gallbladder cancer has been studied separately
or exclusively, the results have also been conflicting. A case–-
control study (31 cases of gallbladder cancer and 3702 con-
trols) found an increased risk of gallbladder cancer following
MHT [14]. That study, however, was not population-based
and the sample size was limited. In line with the results of
this study, a multi-center, case–control study reported a bor-
derline significantly decreased risk of gallbladder cancer (196
cases and 1515 controls) following MHT exposure [28].
Similar results were seen in a previous Swedish study, in
which 23 gallbladder cancer cases were identified in a little
over 22,000 women exposed to MHT [29]. Gallstone disease
was not considered in that study, however.
Table 2. Menopausal hormone therapy (MHT) and risk of biliary tract cancer by sub-site, expressed as odds ratios (OR) with 95% confidence intervals.
Matched cohort
All MHT Estrogen only Estrogen and progestin combination
OR (95 % CI) OR (95 % CI) OR (95 % CI)
Gallbladder cancer (all) 0.58 (0.43–0.78) 0.65 (0.46–0.93) 0.46 (0.28–0.78)
Gallbladder cancer (excluding those with prior gallstones) 0.84 (0.60–1.15) 0.91 (0.62–1.35) 0.73 (0.43–1.23)
Gallbladder cancer (if prior history of gallstones) 0.13 (0.05–0.36) 0.21 (0.08–0.58) –a
Cancer of the extra-hepatic bile duct and the Ampulla 0.83 (0.61–1.15) 0.74 (0.48–1.14) 0.97 (0.63–1.51)
Gallstone disease 6.95 (6.64–7.28) 7.18 (6.79–7.59) 6.83 (6.47–7.21)
aEstimates could not be calculated since no cases were recorded in the exposed group.
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The results of the present study suggested that MHT
reduces the risk of gallbladder cancer, but the association
did not remain after adjustment for gallstone disease.
Gallstone disease is a risk factor for gallbladder cancer
[32,33], and MHT increases the risk of gallstone disease
according to the present study and several others [4,34]. The
indicator for gallstone disease in the present study will not
identify clinically silent gallstone disease. However, it is
unknown if the increased risk of gallbladder cancer due to
gallstone disease is similar in symptomatic and asymptomatic
patients [35,36]. Cholecystectomy for the treatment of symp-
tomatic gallstone disease in women exposed to MHT is a
plausible explanation for the reduced risk of gallbladder can-
cer observed in this study when not adjusting for gallstone
disease. Importantly, if the risk of symptomatic gallstone dis-
ease after MHT initiation was unrelated to the outcome, no
association between MHT and gallbladder cancer would have
been observed. Thus, it seems that MHT results in an
increased risk of symptomatic gallstone disease in women
susceptible to develop gallbladder cancer, i.e., gallstone dis-
ease may be an intermediate step in the development of
gallbladder cancer in women using MHT.
To our knowledge, only one previous study has investi-
gated the risk of extra-hepatic bile duct cancers after MHT
exposure specifically and no association was found [37]. This
lack of association is supported by the present study.
In conclusion, the findings of this large population-based
cohort study controlling for several potential confounding
factors did not support the hypothesis of an increased risk of
BTC associated with contemporary MHT.
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